title: [Anti-NMDA receptor paraneoplastic encephalitis: complete recovery after ovarian teratoma removal].
abstract: BACKGROUND
  A paraneoplastic syndrome characterized by neuropsychiatric symptoms, involuntary movements and seizures has been recently associated with antibodies targeting NMDA (N-methyl-D-aspartate) receptor in patients with an ovarian teratoma. Severe neurological impairment is frequent and treatment in the intensive care unit is often required because of ventilatory failure and life-threatening autonomic instability. Tumor removal is curative in many cases and neurological improvement is demonstrated shortly after surgery.
  
  
  METHODS
  Here we report on a patient with paraneoplastic encephalitis manifested by unconsciousness and coreo-athetosic movements related to NMDA receptor antibodies associated with an immature ovarian teratoma grade III. She made a complete recovery after oophorectomy, intravenous immunoglobulin and corticosteroids.
  
  
  CONCLUSIONS
  Treatment of paraneoplastic syndromes is based on specific therapy for underlying tumor associated to immunomodulators. As in this case, anti-NMDA encephalitis may significantly improve after tumor removal and intra-venous immunoglobuline.
authors.affiliation: Facultad de Medicina, Universidad de Antioquia, Departamento de Neurología Clínica, Medellín, Colombia. germanreyes77@gmail.com
authors.forename: Germán
authors.initials: G
authors.lastname: Reyes-Botero
authors.forename: Carlos S
authors.initials: CS
authors.lastname: Uribe
authors.forename: Olga E
authors.initials: OE
authors.lastname: Hernandez-Ortiz
authors.forename: Juan
authors.initials: J
authors.lastname: Ciro
authors.forename: Alejandro
authors.initials: A
authors.lastname: Guerra
authors.forename: Josep
authors.initials: J
authors.lastname: Dalmau-Obrador
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000276:immunology; D004660:Encephalitis / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000150:complications* / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D020361:Paraneoplastic Syndromes, Nervous System / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology*; D013724:Teratoma / Q000150:complications* / Q000276:immunology / Q000473:pathology / Q000601:surgery*
chemical_list: D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D016194:Receptors, N-Methyl-D-Aspartate